{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:02:10Z","timestamp":1791810130090,"version":"4.3.4"},"reference-count":130,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T00:00:00Z","timestamp":1456444800000},"content-version":"vor","delay-in-days":56,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008664","name":"Juvenile Diabetes Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Xenotransplantation"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients in whom type 1 diabetes is complicated by impaired awareness of hypoglycemia and recurrent episodes of severe hypoglycemia are candidates for islet or pancreas transplantation if severe hypoglycemia persists after completion of a structured stepped care approach or a formalized medical optimization run\u2010in period that provides access to hypoglycemia\u2010specific education including behavioral therapies, insulin analogs, and diabetes technologies under the close supervision of a specialist hypoglycemia service. Patients with type 1 diabetes and end\u2010stage renal failure who cannot meet clinically appropriate glycemic goals or continue to experience severe hypoglycemia after completion of a formalized medical optimization program under the guidance of an expert diabetes care team are candidates for islet or pancreas transplantation either simultaneously with or after a previous kidney transplant. Similarly, patients with type 2 diabetes and problematic hypoglycemia or renal failure who meet these criteria are considered candidates for islet replacement. Likewise, patients with pancreatectomy\u2010induced diabetes in whom an islet autograft was not available or deemed inappropriate are candidates for islet or pancreas transplantation if extreme glycemic lability persists despite best medical therapy. To justify participation of these transplant candidates in early\u2010phase trials of porcine islet cell products, lack of timely access to islet or pancreas allotransplantation due to allosensitization, high islet dose requirements, or other factors, or alternatively, a more favorable benefit\u2013risk determination associated with the xenoislet than the alloislet or allopancreas transplant must be demonstrated. Additionally, in non\u2010uremic xenoislet recipients, the risks associated with diabetes must be perceived to be more serious than the risks associated with the xenoislet product and the rejection prophylaxis, and in xenoislet recipients with renal failure, the xenoislet product and immunosuppression must not impact negatively on renal transplant outcomes. The most appropriate patient group for islet xenotransplantation trials will be defined by the specific characteristics of each investigational xenoislet product and related technologies applied for preventing rejection. Selecting recipients who are more likely to experience prolonged benefits associated with the islet xenograft will help these patients comply with lifelong monitoring and other public health measures.<\/jats:p>","DOI":"10.1111\/xen.12228","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T11:34:36Z","timestamp":1456486476000},"page":"60-76","source":"Crossref","is-referenced-by-count":20,"title":["First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes\u2014Chapter 6: patient selection for pilot clinical trials of islet xenotransplantation"],"prefix":"10.1111","volume":"23","author":[{"given":"Bernhard J.","family":"Hering","sequence":"first","affiliation":[{"name":"Department of Surgery Schulze Diabetes Institute University of Minnesota Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"O'Connell","sequence":"additional","affiliation":[{"name":"The Centre for Transplant and Renal Research Westmead Millennium Institute University of Sydney at Westmead Hospital Westmead NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2014.06.008"},{"key":"e_1_2_10_3_1","unstructured":"U.S.Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (CBER).Guidance for Industry: Source Animal Product Preclinical and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans. Available at:http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Xenotransplantation\/ucm074354.htm"},{"key":"e_1_2_10_4_1","unstructured":"European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP).Guideline on Xenogeneic Cell\u2010Based Medicinal Products. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/12\/WC500016936.pdf[accessed on 3 August 2015]."},{"key":"e_1_2_10_5_1","unstructured":"Health Research Council of New Zealand Gene Technology Advisory Committee.Guidelines for Preparation of Applications Involving Clinical Trials of Xenotransplantation in New Zealand. Available at:http:\/\/www.hrc.govt.nz\/sites\/default\/files\/GTAC%20Guidelines%20for%20Preparation%20of%20Applications%20Involving%20Clinical%20Trials%20of%20Xenotransplantation%20in%20NZ.pdf[accessed on 3 August 2015]."},{"key":"e_1_2_10_6_1","unstructured":"U.S.Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research.Considerations for the Design of Early\u2010Phase Clinical Trials of Cellular and Gene Therapy Products: Guidance for Industry. Available at:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM359073.pdf[accessed on 3 August 2015]."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2010.00592.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2009.0545.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2009.00547.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0090"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0102"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010040354"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e32834ee73a"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1686"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1656"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1579"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1245"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0030"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.081041"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00976.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005752"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60204-9"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70073-7"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02486.x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0028"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2009.0042"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0939"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002853"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2411"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303576"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.277818"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1004"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.10.009"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2775"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70226-8"},{"key":"e_1_2_10_36_1","first-page":"9","article-title":"Outcomes for adults with type 1 diabetes referred with severe hypoglycaemia and\/or referred for islet transplantation to a specialist hypoglycaemia service","volume":"47","author":"Byrne ML","year":"2015","journal-title":"Horm Metab Res"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/diab.46.2.249","article-title":"Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long\u2010standing type I diabetes and autonomic neuropathy","volume":"46","author":"Kendall DM","year":"1997","journal-title":"Diabetes"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2337\/diab.43.5.661","article-title":"Pancreas transplantation in diabetic humans normalizes hepatic glucose production during hypoglycemia","volume":"43","author":"Barrou Z","year":"1994","journal-title":"Diabetes"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1991.tb00484.x"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114936"},{"key":"e_1_2_10_41_1","first-page":"21","article-title":"Response of glucagon and insulin secretion to insulin\u2010induced hypoglycemia in Type 1 diabetic patients after pancreas transplantation","volume":"1","author":"Bosi E","year":"1988","journal-title":"Diabetes Nutr Metab"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1620"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3120-9"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2115"},{"key":"e_1_2_10_45_1","unstructured":"U.S.Food and Drug Administration.Guidance for Industry: Considerations for Allogeneic Pancreatic Islet Cell Products. Available at:http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/default.htm. 2008 [accessed on 3 August 2015]."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04038.x"},{"key":"e_1_2_10_47_1","unstructured":"Clinical Islet Transplantation Consortium.www.isletstudy.org."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12250"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12469"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0063"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.126"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0094"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03977.x"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31820437f3"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408214"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0078"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0184"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007273430401"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.7.2060"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.11.3205"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1620"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12872"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e31829ef01a"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02413.x"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037004"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2015-0079"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3033"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.040"},{"key":"e_1_2_10_69_1","unstructured":"Viacyte.VC\u201001TM Combination Product is in the Clinic. Available at:http:\/\/viacytecom\/clinical\/clinical-trials\/2014 [accessed on 3 August 2015]."},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.20.2701"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2009.00546.x"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00542.x"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3089.2003.00067.x"},{"key":"e_1_2_10_74_1","unstructured":"First WHO global consultation on regulatory requirements for xenotransplantation clinical trials Changsha China The Changsha Communiqu\u00e9 19\u201321 November 2008. 2008. Available at:http:\/\/www.who.int\/transplantation\/xeno\/ChangshaCommunique.pdf.pdf[accessed on 3 August 2015]."},{"key":"e_1_2_10_75_1","unstructured":"Food and Drug Administration Center for Biologics Evaluation and Research Cellular Tissue and Gene Therapies Advisory Committee.Summary Minutes of Meeting #47 May 14\u201015 2009: Animal Models for Porcine Islet Xenotransplantation Products Intended to Treat Type 1 Diabetes or Acute Liver Failure. Available at:http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/CellularTissueandGeneTherapiesAdvisoryCommittee\/UCM183597.pdf2009 [accessed on 3 August 2015]."},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1369"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2005.00206.x"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02850.x"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812253106"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03509.x"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03720.x"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04031.x"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111242"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12868"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000069"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13345"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2009.00543.x"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/72162"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm931"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.683201"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03736.x"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04054.x"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12330"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12562"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2007.00419.x"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1770127"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1078942"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12722"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181f6e267"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.3727\/096368913X663550"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317561110"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070150"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2010.00607_3.x"},{"key":"e_1_2_10_104_1","unstructured":"Living Cell Technologies.Diabecell \u2013 development to date. Available at:http:\/\/www.lctglobal.com\/products\/diabecell\/development-to-date[accessed on 16 February 2015]."},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/xen.12102"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001055"},{"key":"e_1_2_10_107_1","unstructured":"Astellas Pharma Global Development I.A study to assess the efficacy and safety of ASKP1240 in de novo kidney transpant recipients. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01780844?term=anti-cd40+kidney+transplantation&rank=32013 [accessed on 3 August 2015]."},{"key":"e_1_2_10_108_1","unstructured":"Novartis Pharmaceuticals.CCFZ533X2201 \u2010 PoC Study in de Novo Renal Transplantation. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02217410?term=anti-cd40+kidney+transplantation&rank=22014 [accessed on 3 August 2015]."},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/xen.12095"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/xen.12019"},{"key":"e_1_2_10_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12744"},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/xen.12124"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/xen.12161"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000228907.12073.0b"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2006.00319.x"},{"key":"e_1_2_10_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.10.004"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2009.10.013"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/xen.12166"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/xen.12174"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-014-0542-9"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v4.i4.216"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.4.955"},{"key":"e_1_2_10_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01658311"},{"key":"e_1_2_10_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199108000-00007"},{"key":"e_1_2_10_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800741013"},{"key":"e_1_2_10_126_1","first-page":"418","article-title":"Total pancreatectomy. An objective analysis of its use in pancreatic cancer","volume":"40","author":"Sarr MG","year":"1993","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_10_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002689900046"},{"key":"e_1_2_10_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2007.09.004"},{"key":"e_1_2_10_129_1","doi-asserted-by":"publisher","DOI":"10.1111\/xen.12131"},{"key":"e_1_2_10_130_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1678"},{"key":"e_1_2_10_131_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302886"}],"container-title":["Xenotransplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fxen.12228","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/xen.12228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T03:33:10Z","timestamp":1696044790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/xen.12228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/xen.12228"],"URL":"https:\/\/doi.org\/10.1111\/xen.12228","archive":["Portico"],"relation":{},"ISSN":["0908-665X","1399-3089"],"issn-type":[{"value":"0908-665X","type":"print"},{"value":"1399-3089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}